Drug−drug correlation in T−PLL

1
0.5
0
−0.5
−1

ABC294640
Bisindolylmaleimide I
BAY 80-6946
Doramapimod
Idelalisib
Ruxolitinib
SAR245409
TCS PIM-1 1
CHIR-99021
QNZ
SGI-1776
Sapacitabine
SCH772984
VE-822
Sapanisertib
Quisinostat
Olaparib mesylate
Vismodegib
CYT387
Lenalidomide
AG-1478
NSC 95397
Fedratinib
MK-1775
BMS-536924
Crizotinib
Bexarotene
Selumetinib
GW2580
Cabozantinib
Sorafenib
Dasatinib hydrate
MK-2461
VTP50469
Wnt-C59
AMG-900
BAY-73-4506
NSC-87877
IPI-926
Vismodegib
AZD4547
BMS-777607
LEE011
PCI-24781
PDK2 Activator II
Selinexor
Ponatinib
EGF816
OF-1
Veliparib
PHA-793720
Ibrutinib
TCS2210
BI-2536
Ruxolitinib
GSK690693
AZD8330
PIK-93
JW067-E4
CHIR-124
NAP (phthalimide)
ISRIB (trans−isomer)
CUDC-101
OTX-015
OICR-574 (Menin−MLL inhibitor)
AG-014699
DMH-1
MI-463
PAZOPANIB
CX-5461
Temsirolimus
Linifanib
IWR-1-endo
Vatalanib
Axitinib
Methotrexate
Lapatinib
KW-2449
Nilotinib
Mitoxantrone
Vismodegib
MK-1775
FTI-277 HCl
Vandetanib
Cabozantinib
ML-329981
PCI-32765
Ponatinib
AT-9283
NSC-74859
Navitoclax
NSC-87877
Bosutinib
CUDC-907
CYT387
GW843682X
Etoposide
Fidarestat
Sapacitabine
Quisinostat
Dimethylfumarate
KW-2449
Bosutinib
CUDC-907
Ponatinib
Ruxolitinib
Cediranib
Marinostat
Volasertib
Brefeldin A
Sorafenib
Prednisolone
Bexarotene
Erlotinib
PD-0325901
Axitinib
Nilotinib
Ponatinib
Tetrandrine
Idelalisib
Ruxolitinib
Ponatinib
Lenvatinib
Flavopiridol
PD-0325901
Regorafenib
Cediranib
Linifanib
Sorafenib
Tivozanib
Dasatinib
Linifanib
BAY 61-3606
Ponatinib
Axitinib
Crizotinib
BAY 11-7085
PHA-793887
Tivozanib
Cediranib
Ponatinib
Dasatinib
Ruxolitinib
Sorafenib
Foretinib
Ponatinib
Ruxolitinib
Sorafenib
Tivozanib
Linifanib
Cediranib
Ponatinib
Ruxolitinib
Sorafenib
Linifanib
Tivoz